Serum protein binding of tolterodine and its major metabolites in humans and several animal species

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 2, 1999, Pages 91-99

  Påhlman, Ingrid ^a,b   Gozzi, Peter ^a  

^a Pharmacia and Upjohn AB ^*  (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

1 acid glycoprotein; Protein binding; Tolterodine

Indexed keywords

DRUG METABOLITE; HUMAN SERUM ALBUMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OROSOMUCOID; TOLTERODINE;

ANIMAL CELL; ARTICLE; CAT; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RABBIT; RAT;

ADULT; ANIMALS; BENZHYDRYL COMPOUNDS; CATS; CRESOLS; DOGS; ERYTHROCYTES; FEMALE; HUMANS; KINETICS; MALE; MICE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; OROSOMUCOID; PHENYLPROPANOLAMINE; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; SPECIES SPECIFICITY;

EID: 0344267753     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y     Document Type: Article

References (31)

1. H. Naerger, C.H. Fry and L. Nilvebrant, Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders. Neurourol. Urodyn., 14, 524-526 (1995).
2. L. Nilvebrant, K.-E. Andersson, P.-G. Gillberg, M. Stahl and B. Sparf, Tolterodine - a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol., 327, 195-207 (1997).
3. M.M.S. Stahl, B. Ekström, B. Sparf, A. Mattiasson and K.-E. Andersson, Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn., 14, 647-655 (1995).
4. U. Jonas, K. Höfner, H. Madersbacher and the participants of the international study group, Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J. Urol., 15, 144-151 (1997).
5. L. Rentzhog, S.L. Stanton, L. Cardozo, E. Nelson, M. Fall and P. Abrams, Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br. J. Urol., 81, 42-48 (1998).
6. P.E.V.A. Van Kerrebroeck, G. Amarenco, J.W. Thüroff, H.G. Madersbacher, M.T.W.T. Lock, E.J. Messelink and J.M. Soler, Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol. Urodyn., 17, 499-512 (1998).
7. S.H.G. Andersson, A. Lindgren and H. Postlind, Biotransformation of tolterodine, a new antimuscarinic agent, in mouse, rat and dog. Drug Metab. Dispos., 26, 528-535 (1998).
8. H. Postlind, Å. Danielson, A. Lindgren and S.H.G. Andersson, Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab. Dispos., 26, 289-293 (1998).
9. L. Nilvebrant, P.-G. Gillberg and B. Sparf, Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol. Toxicol., 81, 169-172 (1997).
10. M. Rowland and T.N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 3rd edn, Williams & Wilkins, Philadelphia, 1995.
11. D.J. Edwards, D. Lalka, F. Cerra and R.L. Slaughter, Alpha-1 acid glycoprotein concentration and protein binding in trauma. Clin. Pharmacol. Ther., 31, 62-67 (1982).
12. 1 acid glycoprotein. N. Engl. J. Med., 299, 1435-1439 (1978).
13. N. Brynne, P. Dalén, G. Alván, L. Bertilsson and J. Gabrielsson, Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine Clin. Pharmacol. Ther., 63, 529-539 (1998).
14. H. Imamura, T. Maruyama, H. Okabe, H. Shimada and M. Otagiri, A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red. Pharm. Res., 11, 566-570 (1994).
15. L. Palmér, L. Andersson, T. Andersson and U. Stenberg, Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal., 16, 155-165 (1997).
16. T. Andersson, C. Svanström and L. Palmér, Quantitation of tolterodine metabolites in serum using electrospray ionisation tandem mass spectrometry (LC-ESI-MS/MS). 8th International Symposium on Pharmaceutical and Biomedical Analysis, Orlando, May 1997 (abstract).
17. F. Hervé, S. Urien, E. Albengres, J.-C. Duché and J.-P. Tillement, Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin. Pharmacokinet., 26, 44-58 (1994).
18. W.E. Muller, Drug binding to alpha-1-acid glycoprotein: focus on a single binding site. In Protein Binding and Drug Transport, J.-P. Tillement and E. Lindenlaub (Eds), Schuttauer Verlag, Stuttgart, 1986, pp. 29-47.
19. D.R. Abernethy and L. Kerzner, Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J. Am. Geriatr. Soc., 32, 705-708 (1984).
20. 1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin. Pharmacol. Ther., 47, 366-370 (1990).
21. P.D. Kroboth, R.B. Smith, M.I. Sorkin, M.R. Silver, R. Rault, M. Garry and R.P. Juhl, Triazolam protein binding and correlation with alpha-1 acid glycoprotein concentration. Clin. Pharmacol. Ther., 36, 379-383 (1984).
22. K.M. Piafsky, Disease-induced changes in the plasma binding of basic drugs. In Handbook of Clinical Pharmacokinetics, M. Gibaldi and L. Prescott (Eds), Adis Health Science Press, Hong Kong, 1983, pp. 70-88.
23. 1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther., 22, 545-549 (1977).
24. P.A. Routledge, The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol., 22, 499-506 (1986).
25. 1-Acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br. J. Clin. Pharmacol., 32, 311-315 (1991).
26. S.M. Owens, M. Mayersohn and J.R. Woodworth, Phencyclidine blood protein binding: influence of protein, pH and species. J. Pharmacol Exp. Ther., 226, 656-660 (1983).
27. G. Sager, R. Jaeger and C. Little, Binding of prazosin to alpha 1-acid glycoprotein and albumin: effect of protein purity and concentrations. Pharmacol. Toxicol., 64, 365-368 (1989).
28. W.G. Shin, M.G. Lee, M.H. Lee and N.D. Kim, Factors influencing the protein binding of vancomycin. Biopharm. Drug. Dispos., 12, 637-646 (1991).
29. 1-acid glycoprotein. Br. J. Clin. Pharmacol., 36, 241-249 (1993).
30. N. Brynne, M.M.S. Stahl, B. Hallén, P.-O. Edlund, L. Palmér and J. Gabrielsson, Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for urinary bladder overactivity. Int. J. Clin. Pharmacol. Ther., 35, 287-295 (1997).
31. G. Larsson, B. Hallén and L. Nilvebrant, Tolterodine in the treatment of overactive bladder. Analysis of the pooled phase II efficacy and safety data. Urology (1998), in press.